drugset / Trial / NCT07364344

Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.

NCT07364344

Not yet recruiting 57 enrolled Ji Xunming,MD,PhD
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, dose-escalation and dose-expansion Phase I study designed to evaluate the safety of hibernation-like therapy (Chlorpromazine and Promethazine, C+P) and observe improvements in infarct volume in patients with AIS eligible for reperfusion therapy.

Timeline

Start
2026-01
Primary completion
2026-07
Completion
2026-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorpromazine Small molecule 50 mg Intravenous
Subject Chlorpromazine Small molecule 62.5 mg Intravenous
Subject Chlorpromazine Small molecule 75 mg Intravenous
Subject Chlorpromazine Small molecule 100 mg Intravenous
Subject Promethazine Small molecule 50 mg Intravenous
Subject Promethazine Small molecule 62.5 mg Intravenous
Subject Promethazine Small molecule 75 mg Intravenous
Subject Promethazine Small molecule 100 mg Intravenous

Indications